Covered recipient · General Payments record
MALGORZATA KALUZA
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$9,215.71
- Reported across 375 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $625.34 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Acerta Pharma LLC | $262.35 | 3 |
| Amgen Inc. | $208.73 | 6 |
| Lilly USA, LLC | $85.72 | 4 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.40 | 1 |
| ABBVIE INC. | $21.48 | 1 |
| Merck Sharp & Dohme Corporation | $17.66 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $21.48 | 01/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104023229 | CMS |
| Amgen Inc. | $18.28 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117292120 | CMS |
| Amgen Inc. | $121.93 | 03/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117292128 | CMS |
| Amgen Inc. | $6.31 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117292122 | CMS |
| Amgen Inc. | $17.07 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117292124 | CMS |
| Amgen Inc. | $23.57 | 06/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1111613305 | CMS |
| Amgen Inc. | $21.57 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117292126 | CMS |
| AstraZeneca Pharmaceuticals LP | $122.40 | 02/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105590258 | CMS |
| AstraZeneca Pharmaceuticals LP | $12.98 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105494379 | CMS |
| AstraZeneca Pharmaceuticals LP | $126.97 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104608464 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $29.40 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118052957 | CMS |
| Lilly USA, LLC | $18.64 | 04/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135162955 | CMS |
| Lilly USA, LLC | $13.30 | 05/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135103205 | CMS |
| Lilly USA, LLC | $26.63 | 07/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135140400 | CMS |
| Lilly USA, LLC | $27.15 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135162279 | CMS |
| Merck Sharp & Dohme LLC | $17.66 | 08/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141955259 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.